Abbott Lands FISH Technology For Cancer DNA Probe Tests With Vysis Buy
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories is expanding its molecular diagnostics offerings to include tests for cancer and other genetic diseases through the $355 mil. cash acquisition of Vysis under a definitive agreement, announced Oct. 24.
You may also be interested in...
Cepheid Charge Into Clinical Diagnostics Led By Ex-Vysis Executives
Cepheid expects its clinical test for group B strep to reach the U.S. market early in 2003, marking the life sciences firm's entry into clinical testing for infectious diseases
Cepheid Charge Into Clinical Diagnostics Led By Ex-Vysis Executives
Cepheid expects its clinical test for group B strep to reach the U.S. market early in 2003, marking the life sciences firm's entry into clinical testing for infectious diseases
Lung Cancer Nucleic Acid Test Clinicals Under Development By DiagnoCure
DiagnoCure says its R&D collaboration with Compugen Ltd. will spur the launch of pivotal clinical studies evaluating a nucleic acid-based test for lung cancer by mid-2003